Back to Results

GSK plc (GLAXF)

GSK plc is a healthcare company engaged in the research, development, and manufacture of medicines and vaccines. Through its Commercial Operations and Total R&D segments, the company develops specialty medicines, vaccines, and general medicines for use in the United Kingdom, the United States, and other international markets. Its specialty medicines portfolio includes treatments in oncology, respiratory and immunology, inflammation, and inhaled therapies, as well as products for HIV and several other disease areas. GSK also supplies vaccines covering indications such as shingles, meningitis, RSV, influenza, hepatitis, and a range of childhood and infectious diseases. In addition, the company markets general medicines for conditions including asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin disorders. GSK is headquartered in London, United Kingdom, and was formerly known as GlaxoSmithKline plc before adopting its current name in 2022.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Payment Date Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-GLAX.F
$30.23
21.2% Upside
Undervalued
Not available
Not available
Great
October 8, 2026
3.7%
October 28, 2026
15.8x
4.3x
2.3x
101.9 B
119.4 B
19.4%
96.9%
5.7
55.3%
143.1%
Valuation • Fair Value

GSK plc (OTC-GLAX.F) Fair Value by Valuation Model

Review the available estimates for GSK plc (OTC-GLAX.F), including Ben Graham Formula Value, DDM Fair Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$30.23

Estimated upside of 21.2% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

Ben Graham Formula Value

$17.87

Classic Ben Graham valuation formula reference.

DDM Fair Value

$38.25

Dividend discount model valuation reference.

EPV Fair Value

$39.81

Earnings power value estimate.

Comps Fair Value

$27.29

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 6 available valuation references for GSK plc (OTC-GLAX.F) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for GSK plc (OTC-GLAX.F)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

44.041 B

Current operating scale indicator.

Revenue Forecast

45.316 B

Forward revenue estimate.

EBITDA

14.349 B

Current operating profitability reference.

EBITDA Forecast

15.315 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review GSK plc (OTC-GLAX.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for GSK plc (OTC-GLAX.F)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

7

Relatively strong quality score.

Beneish M-Score

-2.60

No elevated caution signal from this screen.

Altman Z-Score

5.7

Relatively strong balance-sheet zone.

FCF / Net Income

143.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for GSK plc (OTC-GLAX.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for GSK plc (OTC-GLAX.F)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

October 28, 2026

Days to Earnings

36

Dividend Payment Date

October 8, 2026

Dividend Yield

3.7%

Current income yield reference.

Payout Ratio

55.3%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for GSK plc (OTC-GLAX.F), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for GSK plc (OTC-GLAX.F) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for GSK plc (OTC-GLAX.F) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for GSK plc (OTC-GLAX.F) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for GSK plc (OTC-GLAX.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Buy

The monthly technical read for GSK plc (OTC-GLAX.F) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

GSK plc (OTC-GLAX.F) Stock FAQ

Data-supported answers about GSK plc (OTC-GLAX.F), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$30.23
Estimated upside 21.2%
Valuation Rating
Undervalued
Estimated upside of 21.2%
Financial Health
Great
Current financial-health read

The current fair value estimate for GSK plc (OTC-GLAX.F) is $30.23. This implies an estimated upside of 21.2% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 21.2% versus the current market price.

The current financial health read for GSK plc (OTC-GLAX.F) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for GSK plc (OTC-GLAX.F) is October 28, 2026.

Based on the current data, dividend yield is 3.7%, payment date is October 8, 2026.

The current P/E ratio listed for GSK plc (OTC-GLAX.F) is 15.8x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for GSK plc is 101.9 B.

The current enterprise value listed for GSK plc is 119.4 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for GSK plc is OTC-GLAX.F, and the stock is listed on OTC Markets.

GSK plc (OTC-GLAX.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for GSK plc is 19.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for GSK plc is 96.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B
BLTE NASDAQ Belite Bio Inc ADR Fair Value Fair Market Cap 7.062 B